Biomedical Engineering Reference
In-Depth Information
154. Castro MJ, Stam AH, Lemos C, de Vries B, Vanmolkot KR, Barros J, Terwindt GM, Frants
RR, Sequeiros J, Ferrari MD, Pereira-Monteiro JM, van den Maagdenberg AMJM (2009)
First mutation in the voltage-gated Na
V
1.1 subunit gene SCN1A with co-occurring familial
hemiplegic migraine and epilepsy. Cephalalgia 29:308-313
155. Diehgans M, Freilinger T, Eckstein G, Babini E, Lorenz-Depiereux B, Biskup S, Ferrari M,
Herzog T, van den Maagdenberg AMJM, Pusch M, Strom T (2005) Mutation in the neuronal
voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 366:371-377
156. Gargus JJ, Tournay A (2007) Novel mutation confirms seizure locus SCN1A is also familial
hemiplegic migraine. Pediatr Neurol 37:407-410
157. Kahlig KM, Rhodes TH, Pusch M, Freilinger T, Pereira-Monteiro JM, Ferrari MD, van den
Maagdenberg AMJM, Diehgans M, George AC (2008) Divergent sodium channel defects in
familial hemiplegic migraine. Proc Natl Acad Sci USA 105:9799-9804
158. Calabresi P, Galletti F, Rossi C, Sarchielli P, Cupini LM (2007) Antiepileptic drugs in
migraine: from clinical aspects to cellular mechanism. Trends Pharmacol Sci 28:188-195
159. Mankodi A, Thornton CA (2002) Myotonic syndromes. Curr Opin Neurol 15:545-552
160. Harper PS (2001) Myotonic dystrophy. WB Saunders Company, London
161. Lehmann-Horn F, Kuther G, Ricker K, Grafe P, Ballanyi K, Rudel R (1987) Adynamia
episodica hereditaria with myotonia: a noninactivating sodium current and the effect of
extracellular pH. Muscle Nerve 10:363-374
162. Lehmann-Horn F, Rudel R, Ricker K (1987) Membrane defects in paramyotonia congenita
(Eulenburg). Muscle Nerve 10:633-641
163. Dengler R, Rudel R (1979) Effects of tocainide on normal and myotonic mammalian skeletal
muscle. Arzneimittelforschung 29:270-273
164. Streib EW (1986) Successful treatment with tocainide of recessive generalized congenital
myotonia. Ann Neurol 19:501-504
165. R
udel R (1994) Altered excitability of the muscle cell membrane. The non-dystrophic
myotonias. In: Engel AG, Franzini-Armstrong C (eds) Myology. Mc Graw-Hill, New York
166. Trip J, Drost GG, van Engelen BGM, Faber GG (2006) Drug treatment for myotonia.
Cochrane Database Syst Rev. doi:10.1002/14651858.CD004762.pub, John Wiley & Sons,
Ltd
167. Hill RJ, Duff HJ, Sheldon RS (1988) Determinants of stereospecific binding of type I
antiarrhythmic drugs to sodium channels. Mol Pharmacol 34:659-663
168. Franchini C, Carocci A, Catalano A, Cavalluzzi MM, Corbo F, Lentini G, Scilimati A,
Tortorella P, Conte Camerino D, De Luca A (2003) Optically active mexiletine analogues as
stereoselective blockers of voltage-gated Na
+
channels. J Med Chem 46:5238-5248
169. Desaphy J-F, De Luca A, Didonna MP, George AL Jr, Conte Camerino D (2004) Different
flecainide sensitivity of hNa
V
1.4 channels and myotonic mutants explained by state-depen-
dent block. J Physiol 554:321-334
170. Rosenfeld J, Sloan-Brown K, George AL Jr (1997) A novel muscle sodium channel mutation
causes painful congenital myotonia. Ann Neurol 42:811-814
171. Abriel H, Wehrens XHT, Benhorin J, Kerem G, Kass RS (2000) Molecular pharmacology of
the sodium channel mutation D1790G linked to the long-QT syndrome. Circulation
102:921-925
172. Catalano A, Carocci A, Corbo F, Franchini C, Muraglia M, Scilimati A, De Bellis M, De Luca
A, Conte Camerino D, Sinicropi MS, Tortorella V (2008) Constrained analogues of tocainide
as potent skeletal muscle sodium channel blockers toward the development of antimyotonic
agents. Eur J Med Chem 43:2535-2540
173. Herweg B, Steinberg JS (2000) Oral Antiarrhythmic drugs used for arrhythmia prevention.
Card Electrophysiol Rev 4:255-261
174. Franchini C, Corbo F, Lentini G, Bruno G, Scilimati A, Tortorella V, Conte Camerino D, De
Luca A (2000) Synthesis of new 2,6-prolylxylidide analogues of tocainide as stereoselective
blockers of voltage-gated Na
+
channels with increased potency and improved use-dependent
activity. J Med Chem 43:3792-3798
€
